| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$217,353 ) |
| | 2025 | 2022 | GENENTECH INC | 1, DNA WAY | SOUTH SAN FRANCISCO | CA | 94080-4990 | SAN MATEO | USA | U01FD007206 | Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source | 000 | 3 | FDA | 1/30/2025 | -$217,353 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | GENENTECH INC | 1, DNA WAY | SOUTH SAN FRANCISCO | CA | 94080-4990 | SAN MATEO | USA | U01FD007206 | Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source | 000 | 2 | FDA | 6/29/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $260,757 ) |
| | 2022 | 2022 | GENENTECH INC | 1, DNA WAY | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | U01FD007206 | Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source | 001 | 3 | FDA | 8/31/2022 | $232,798 |
| | 2022 | 2022 | GENENTECH INC | 1, DNA WAY | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | U01FD007206 | Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source | 001 | 3 | FDA | 8/31/2022 | $27,959 |
| | 2022 | 2021 | GENENTECH, INC. | 1 DNA WAY | SOUTH SAN FRANCISCO | CA | 94080-4990 | SAN MATEO | USA | U01FD007206 | Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source | 000 | 2 | FDA | 6/7/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $256,284 ) |
| | 2021 | 2021 | GENENTECH, INC. | 1 DNA WAY | SOUTH SAN FRANCISCO | CA | 94080-4990 | SAN MATEO | USA | U01FD007206 | Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source | 000 | 2 | FDA | 7/9/2021 | $256,284 |
|
| Issue Date FY: 2020 ( Subtotal = $251,057 ) |
| | 2020 | 2020 | GENENTECH, INC. | 1 DNA WAY | SOUTH SAN FRANCISCO | CA | 94080-4990 | SAN MATEO | USA | U01FD007206 | Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source | 000 | 1 | FDA | 8/31/2020 | $251,057 |
|
| Issue Date FY: 1998 ( Subtotal = $0 ) |
| | 1998 | 1998 | GENENTECH, INC | 1 DNA WAY | SO SAN FRANCISCO | CA | 94080 | | USA | F32GM019454 | BIOLOGICALLY RELEVANT ALPHA HELIX STABILIZATION | 000 | 1 | NIH | 12/21/1998 | $0 |
|
| Issue Date FY: 1997 ( Subtotal = $24,292 ) |
| | 1997 | | GENENTECH, INC | 1 DNA WAY | SO SAN FRANCISCO | CA | 94080 | | USA | F32DK09755 | PHAGE VS COMBINATORIAL LIBRARY OF BIOTIN ANALOGS | 000 | 01 | NIH | 9/30/1997 | $24,292 |
|
| Issue Date FY: 1996 ( Subtotal = $27,600 ) |
| | 1996 | | GENENTECH, INC | 1 DNA WAY | SO SAN FRANCISCO | CA | 94080 | | USA | F32GM16549 | SEMISYNTHETIC ENGINEERING OF HUMAN GROWTH HORMONE | 000 | 03 | NIH | 11/30/1995 | $27,600 |
|
| Issue Date FY: 1995 ( Subtotal = $22,700 ) |
| | 1995 | | GENENTECH, INC | 1 DNA WAY | SO SAN FRANCISCO | CA | 94080 | | USA | F32GM16549 | SEMISYNTHETIC ENGINEERING OF HUMAN GROWTH HORMONE | 000 | 02 | NIH | 12/10/1994 | $22,700 |
|
|
